To Be Discontinued Powder Cardiovascular
Cholestyramine Powder · 3 active FDA presentation rows for this drug
Brand: PREVALITE
FDA lists Cholestyramine Powder as To Be Discontinued (Upsher-Smith Laboratories, LLC).
No availability text on this FDA row.
Cholestyramine Powder: To Be Discontinued
FDA availability text is not recorded on this row. 3 shortage presentations are tracked for this drug. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Cholestyramine Powder
- Manufacturer
- Upsher-Smith Laboratories, LLC
- Dosage Form
- Powder
- Presentation
- Prevalite, Powder, 4 g/5.5 g (NDC 0245-0036-60)
- Package NDC
- 0245-0036-60
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- May 14, 2025
- Last Updated
- May 14, 2025
- Therapeutic Category
- Cardiovascular
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
A business decision was made to discontinue the product.
Full Drug Profile
cholestyramine
Side effects, interactions, warnings & more
Nearby, Other Cholestyramine Shortage Records
FDA reason on file: A business decision was made to discontinue the product. General shortage guidance lives on the tracker hub.